Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632736 · ClinicalTrials.gov registry record · Phase 3
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
A Phase 3 study of Parkinson Disease and Parkinson's Disease, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
- 20
- Study locations
NCT00632736: Completed Phase 3 study of Parkinson Disease and Parkinson's Disease, sponsored by GlaxoSmithKline.
NCT00632736 is a Phase 3 study of Parkinson Disease and Parkinson's Disease that has completed, run by GlaxoSmithKline. The registered enrollment target is 419 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00632736, a Phase 3 study of Parkinson Disease and Parkinson's Disease, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
Primary Outcome
AEs, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, were collected to obtain data on the safety, tolerability, and benefit of ropinirole XL. SAEs, defined as AEs that are fatal, life threatening, disabling/incapacitating, resulting in hospitalization or prolongation of a hospital stay, a congenital abnormality/birth defect, or any important medical occurrence that the investigator regards as serious based on medical
Conditions Studied
Interventions
- DRUG Ropinirole XL (formerly CR)
Study Locations (20)
Florida
- GSK Investigational Site - Boca Raton
- GSK Investigational Site - Panama City
- GSK Investigational Site - Port Orange
- GSK Investigational Site - St. Petersburg
- GSK Investigational Site - Tampa
Michigan
- GSK Investigational Site - Bingham Farms
- GSK Investigational Site - Southfield
- GSK Investigational Site - Traverse City
California
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - San Francisco
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Augusta
Alabama
- GSK Investigational Site - Birmingham
Colorado
- GSK Investigational Site - Englewood
Illinois
- GSK Investigational Site - Glenview
Kansas
- GSK Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2004-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00632736 record still lists
NCT00632736 is an interventional study that assigns participants to a tested intervention. The registered 419 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Ropinirole XL (formerly CR) is the first listed.
NCT00632736 names 20 study sites across 12 states, led by Florida, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT00632736 about?
NCT00632736 is a clinical study titled "An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease". To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease
What is the current status of trial NCT00632736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2004-02. Estimated completion is 2010-03.
What conditions does trial NCT00632736 study?
This clinical trial studies the following conditions: Parkinson Disease, Parkinson's Disease.
What interventions are being tested in trial NCT00632736?
The interventions under investigation include: Ropinirole XL (formerly CR) (DRUG).
Who is sponsoring clinical trial NCT00632736?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00632736 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00632736's enrollment target sits among peer trials
419 28th of 297 higher than 270 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Flexible-Dose Trial in Early Parkinson's Disease (PD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05579639 · 419 participants · Phase 2
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia